This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

An Inside Look at Biotech Investor Pros Dealing With Market Meltdown

Last night, I exchanged emails with a number of investors who run dedicated health care funds. I wanted to know how they navigated Monday's market selloff.

Biotech Stocks Recover From Early-Morning Flash Crash

The iShares Nasdaq Biotechnology Index (IBB), the most closely followed biotech sector index, is down less than 1% after a deep plunge at Monday's open.

Northwest Bio Forced to Temporarily Halt Enrollment of Brain Tumor Vaccine Study (Update)

Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.

Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio

Biotech columnist Adam Feuerstein answers readers' questions about health care.

MannKind Financial Woes Escalate on Failed Debt Settlement

The slow commercial launch of Afrezza, MannKind's inhaled mealtime insulin, continues to be the root cause of the company's balance-sheet woes.

Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief

Speculative biotech stocks that were huge winners for healthcare investors earlier this year are now down significantly from their 52-week highs.

Biotech Stock Mailbag: Controversial Stocks Revisited

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Seven Reasons to Love Biomarin's Duchenne Drug Falls One Short

RBC Capital analyst Michael Yee offers seven reasons why Biomarin Pharmaceuticals will secure U.S. approval for drisapersen to treat Duchenne muscular dystrophy, a rare, genetic muscle-wasting disease.

Intra-Cellular Keeps Investors in Dark About Schizophrenia Drug Study

Investors asking Intra-Cellular for a copy of the scientific poster needed to conduct proper due diligence on ITI-007 are told they can't have it.

MannKind Afrezza Sales Underwhelming Again, Sanofi Reports

The only saving grace is that no one, not even the most Kool-Aid-drinking MannKind supporter, is surprised by Afrezza's poor sales.

Page 4 of 343
Top Rated Stocks Top Rated Funds Top Rated ETFs